US · Healthcare · Biotechnology
EPS came in at -1.99 against a street estimate of -2.55 — a beat of 22.0%.
Analysts rate Madrigal Pharmaceuticals Inc a buy (13 buy, 1 hold, 1 sell out of 15) with an average price target of $678.06.
CONFIDENT Rezdiffra Q2 sales hit $364M (+71% YoY), surpassing 50k patients. Company building mega-blockbuster pipeline with 10+ programs anchored on foundational therapy. F4c outcomes trial tracking to 2027 readout. Q2 2026 U.S. driving all material revenue. Europe launches in Germany, early access France, approval UK, but reimbursement headwinds and MFN pricing uncertainty limit near-term contribution. Management says contribution will remain negligible for 2026. Analysts pressed on timing precision for F4c trial, competitive positioning vs. lanifibranor, and European reimbursement. Management deflected F4c specificity citing pioneering nature of trial, emphasized real-world performance superiority over competitors, acknowledged Europe headwinds but dismissed near-term impact. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| Baker Bros Advisors LP | 9.27% |
| HHG PLC | 8.74% |
| RTW INVESTMENTS, LLC | 8.63% |
| venBio Select Advisor LLC | 7.87% |
| BlackRock Inc | 6.75% |
| Paulson & Company Inc | 5.80% |
| Vanguard Portfolio Management, LLC | 3.64% |
| Vanguard Capital Management, LLC | 3.58% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 MADRIGAL PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Board expanded from 8 to 9 members on August 11, 2026 • New director compensati | 2026-08-12 |
| Quarterly report · Q2 2026 MADRIGAL PHARMACEUTICALS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Product Revenue (6 months ended June 30, 2026): $675.6 million vs. $350.1 m | 2026-07-30 |
| Results announced · Q3 2026 MADRIGAL PHARMACEUTICALS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Rezdiffra net sales: $364.3 million, up 71% year-over-year (Q2 2025: $2 | 2026-07-30 |
| Board / officer change · Q2 2026 MADRIGAL PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Record date for Annual Meeting: April 23, 2026 • Total shares outstanding as of | 2026-06-17 |
| Quarterly report · Q1 2026 MADRIGAL PHARMACEUTICALS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Product revenue (Q1 2026): $311.3 million vs. $137.3 million (Q1 2025) – 12 | 2026-05-06 |
| Results announced · Q2 2026 MADRIGAL PHARMACEUTICALS Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 2026 Rezdiffra net sales: $311.3 million — up 127% year-over-year from $137. | 2026-05-06 |
| Proxy statement · Q2 2026 MADRIGAL PHARMACEUTICALS, INC. – 2026 PROXY SUMMARY FOR RETAIL INVESTORS --- CEO COMPENSATION & CHANGES • CEO Bill Sibold's 2025 total compensation | 2026-04-28 |
| Annual report FY2025 MADRIGAL PHARMACEUTICALS, INC. — FORM 10-K SUMMARY Fiscal Year Ended December 31, 2025 --- HEADLINE NUMBERS • Product Revenue 2025: $958.4 million | 2026-02-19 |
Readable in the app.
| Announcement | Date |
|---|---|
| Entered into material definitive agreement with Roche Madrigal Pharmaceuticals amended its 2008 research and commercialization agreement with Roche on January 29, 2026. Under the amendment, Madrigal gains full control over patent term adjustmen | 2026-01-30 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Madrigal Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.